LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT00567619
Collaborator
(none)
900
1
Study Details
Study Description
Brief Summary
Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency & severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting to specialists, especially internists
- Evaluate effect of treatment with a acid suppressive therapy on these parameters: looking for improvement of symptom burden and quality of life according to the GERD impact sca
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Time Perspective:
Prospective
Official Title:
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
Study Start Date
:
Jul 1, 2007
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Patients with newly occured upper GI symptoms related to GERD
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Research Site | Vienna | Austria |
Sponsors and Collaborators
- AstraZeneca
Investigators
- Study Chair: Not required for Study, Not required for this study
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00567619
Other Study ID Numbers:
- NIS-GAT-NEX-2007/1
First Posted:
Dec 5, 2007
Last Update Posted:
Feb 18, 2008
Last Verified:
Feb 1, 2008